Evaluating Anti-Tumor Efficacy of Cetuximab and MM-121 in Xenograft Model

The animal experimental protocol was approved by the Institutional Animal Care and Use Committees of Emory University. In brief, 4×10⁶ Tu212 and 2×10⁶ SCC47 cells (1:1 in matrigel) were injected subcutaneously into female nude mice (athymic nu/nu, Taconic, NY) aged 4 to 6 weeks. Mice were randomly divided into 6 groups after tumor formation: PBS control, cetuximab 6.25μg/dose, MM-121 300μg/dose (MM-121.LD), MM-121 600μg/dose (MM-121.HD), combination with low dose MM-121 (comb. LD) and combination with high dose MM-121 (comb. HD) (n=7 for each treatment group). Doses were chosen based on previous studies (19 (link), 25 (link)). Drugs were given by intraperitoneal injection (I.P.) twice a week. Tumor volume and bodyweight were measured three times a week. Tumor volume was calculated using the formula: V= π/6×larger diameter ×(smaller diameter)² as reported previously (25 (link)). Major organs were harvested for toxicity evaluation by hematoxylin and eosin (H&E) staining.

Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link: Access Free Full Text.

Jiang N., Wang D., Hu Z., Shin H.J., Qian G., Rahman M.A., Zhang H., Amin A.R., Nannapaneni S., Wang X., Chen Z., Garcia G., MacBeath G., Shin D.M., Khuri F.R., Ma J., Chen Z.G, & Saba N.F. (2014). Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma (HNSCC). Molecular cancer therapeutics, 13(7), 1826-1836.

Publication 2014

athymic nu/nu

Animal Athymic Bodyweight Cells Cetuximab Comb Drugs Eosin Female Hematoxylin Institutional animal care and use committees Intraperitoneal injection Matrigel Mice Mm 121 Nu nu Tumor

Corresponding Organization :

Other organizations : Sun Yat-sen University, Sun Yat-sen University Cancer Center, Emory University, Quest Diagnostics (United States), Merrimack Pharmaceuticals (United States)

Top 5 similar protocols

Protocol cited in 2 other protocols

Variable analysis

independent variables

Cetuximab 6.25μg/dose
MM-121 300μg/dose (MM-121.LD)
MM-121 600μg/dose (MM-121.HD)
Combination with low dose MM-121 (comb. LD)
Combination with high dose MM-121 (comb. HD)

dependent variables

Tumor volume
Bodyweight

control variables

Female nude mice (athymic nu/nu, Taconic, NY) aged 4 to 6 weeks
Subcutaneous injection of 4×10^6 Tu212 and 2×10^6 SCC47 cells (1:1 in matrigel)
PBS control

controls

Positive control: PBS control
Negative control: Not explicitly mentioned

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!